CD5 ablation enhances persistence and antitumor potency of engineered T cells by mitigating exhaustion and promoting cytotoxicity.

J Immunother Cancer · 2025 · PMC12666075 · PMID 41320226

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a decreasing trendno p-value reported

Within the CD4 + population, the CD4-Tn-CCR7 subset displayed a decreasing trend, while the CD4-Tem-GZMK subset increased significantly.

also in 47,180 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.